Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop M. Kantarjian, Susan O’Brien, Luis Fayad et al.|The Lancet Oncology|2012Cited by 411
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE studyHagop M. Kantarjian, Anjali S. Advani, Daniel J. DeAngelo et al.|Cancer|2019Cited by 327
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in AdultsMark R. Litzow, Martin S. Tallman, Zhuoxin Sun et al.|New England Journal of Medicine|2024Cited by 213
Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic LeukemiaStuart E. Siegel, Archie Bleyer, Wendy Stock et al.|JAMA Oncology|2018Cited by 168
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Hagop Kantarjian, Nicola Gökbuget et al.|Leukemia Research|2019Cited by 52